Mersana Therapeutics, Inc.
MRSNDelisted Jan 6, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001442836
Mersana Therapeutics, Inc. was delisted on Jan 6, 2026; its insiders filed their last Form 4 on Jan 6, 2026; 51 institutions reported holding it in 13F filings for Q4 2025, worth $64.8M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Mersana Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Mersana Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Mott David M | Director | 0Indirect | Jan 6, 2026 | 1 |
| Hege Kristen | Director | 0 | Jan 6, 2026 | 1 |
| Dere Willard H | Director | 0 | Jan 6, 2026 | 1 |
| Protopapas Anna | Director | 0Indirect | Jan 6, 2026 | 1 |
| Alleva Lawrence M | Director | 0Indirect | Jan 6, 2026 | 1 |
| Carvajal Alejandra | SVP, Chief Legal Officer | 0 | Jan 6, 2026 | 1 |
| Huber Martin H. Jr. | President, CEO | 0 | Jan 6, 2026 | 1 |
| Hack Andrew A. F. | Director | 0Indirect | Jan 6, 2026 | 1 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer | 0 | Jan 6, 2026 | 1 |
| Diaz Allene M. | Director | 0 | Jan 6, 2026 | 1 |
| DeSchuytner Brian | SVP, COO & CFO | 0 | Jan 6, 2026 | 1 |
| Mandelia Ashish | VP, Chief Accounting Officer | 0 | Jan 6, 2026 | 1 |
| Bala Mohan | SVP, Chief Development | 0 | Jan 6, 2026 | 2 |
| EcoR1 Capital, LLC | 10% Owner | 11,328,000Indirect | Dec 23, 2024 | 0 |
| Misra Tushar | SVP, Chief Manuf. Officer | 17,966 | Jan 17, 2024 | 0 |
| Yang Arvin | SVP, Chief Medical Officer | 30,821 | Jan 18, 2023 | 0 |
| Kaufman Michael J. | Chief Manufacturing Officer | 32,622 | Jul 19, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Mandelia AshishVP, Chief Accounting Officer | SSale | −1.01K | $0.66 | −$664.62 | −2.0%49.4K after | 10b5-1 |
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Protopapas AnnaDirector | SSale | −11.5K | $0.66 | −$7.61K | −7.4%144.9K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | Carvajal AlejandraSVP, Chief Legal Officer | SSale | −952 | $0.63 | −$599.76 | −1.3%70.9K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | DeSchuytner BrianSVP, COO & CFO | SSale | −2.33K | $0.63 | −$1.47K | −2.1%109.0K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | Lowinger Timothy BSVP, Chief Sci.&Tech. Officer | SSale | −1.79K | $0.63 | −$1.13K | −0.7%245.9K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | Mandelia AshishVP, Chief Accounting Officer | SSale | −1.79K | $0.63 | −$1.13K | −3.3%52.4K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | Protopapas AnnaDirector | SSale | −6.19K | $0.63 | −$3.90K | −3.8%155.4K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Bala MohanSVP, Chief Development Officer | SSale | −5.94K | $0.58 | −$3.44K | −7.9%68.9K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Carvajal AlejandraSVP, Chief Legal Officer | SSale | −5.10K | $0.58 | −$2.96K | −6.1%78.3K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | DeSchuytner BrianSVP, COO & CFO | SSale | −8.47K | $0.58 | −$4.91K | −6.5%121.4K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Huber Martin H. Jr.President, CEO | SSale | −4.51K | $0.58 | −$2.62K | −3.5%122.9K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Lowinger Timothy BSVP, Chief Sci.&Tech. Officer | SSale | −8.05K | $0.58 | −$4.67K | −3.0%257.7K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Protopapas AnnaDirector | SSale | −8.64K | $0.58 | −$5.01K | −4.9%168.0K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Mandelia AshishVP, Chief Accounting Officer | SSale | −3.55K | $0.58 | −$2.06K | −5.8%57.5K after | 10b5-1 |
| Sep 15, 2025 (view filing) | Sep 12 | 3 days | Huber Martin H. Jr.President, CEO | SSale | −2.01K | $7.31 | −$14.7K | −17.4%9.57K after | 10b5-1 |
| Oct 28, 2025 (view filing) | Oct 27 | 1 day | Bala MohanSVP, Chief Development Officer | SSale | −77 | $9.90 | −$762.3 | −2.6%2.92K after | 10b5-1 |